相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors
Haleema Sadia Malik et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736
Andrew S. Moore et al.
BLOOD ADVANCES (2020)
Gilteritinib improves outcomes in AML
Peter Sidaway
Nature Reviews Clinical Oncology (2019)
FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist
Rita Assi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
Ellen L. Weisberg et al.
ONCOTARGET (2017)
Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis
M. Kamran et al.
ONCOGENESIS (2017)
Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification
Krishna V. Komanduri et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations
Weiguo Zhang et al.
CANCER RESEARCH (2016)
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
Katherine A. Minson et al.
JCI INSIGHT (2016)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Aurora Kinase inhibitors: Current Status and Outlook
Vassilios Bavetsias et al.
FRONTIERS IN ONCOLOGY (2015)
AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
Cong Li et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Julie A. Zorn et al.
PLOS ONE (2015)
Go6976, a FLT3 kinase inhibitor, exerts potent cytotoxic activity against acute leukemia via inhibition of survivin and MCL-1
Akira Yoshida et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations
Yesid Alvarado et al.
CANCER (2014)
Facile Identification of Dual FLT3-Aurora A Inhibitors: A Computer- Guided Drug Design Approach
Yung Chang Hsu et al.
CHEMMEDCHEM (2014)
Aurora kinase inhibitor patents and agents in clinical testing: an update (2011-2013)
Chun Hei Antonio Cheung et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells
Vassilios Bavetsias et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Mark Levis
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A. S. Moore et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
Bob Lowenberg et al.
BLOOD (2011)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells
Martin Grundy et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
A. S. Moore et al.
LEUKEMIA (2010)
Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents
John R. Pollard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The Aurora kinase family in cell division and cancer
Gerben Vader et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2008)
Aurora kinases as anticancer drug targets
Oliver Gautschi et al.
CLINICAL CANCER RESEARCH (2008)
Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A:: A novel pharmacodynamic method for measuring aurora a activity
Patrick J. LeRoy et al.
CANCER RESEARCH (2007)
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
Mark G. Manfredi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Aurora kinases: shining lights on the therapeutic horizon?
PD Andrews
ONCOGENE (2005)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Survivin, versatile modulation of cell division and apoptosis in cancer
DC Altieri
ONCOGENE (2003)
FLT3 mutations in acute myeloid leukemia cell lines
H Quentmeier et al.
LEUKEMIA (2003)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7
S Shin et al.
BIOCHEMISTRY (2001)
分享论文
